Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sanjay Sethi, Antony Wright, Elisabeth Sophia Hartgers-Gubbels, Marlene Hechtner, Brendan Clark, Ciara Wright, Sue Langham & Roland Buhl. (2022) Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2149-2160.
Read now
Read now
Victoria Neches García, Laura Amanda Vallejo-Aparicio, Afisi S Ismaila, Antoni Sicras-Mainar, Aram Sicras-Navarro, Cruz González, Rafael Cuervo, Soham Shukla & Marcos García-Peñuela. (2022) Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2161-2174.
Read now
Read now
Ronald F. Grossman. (2021) Blood eosinophils in COPD to predict exacerbations and inform inhaled corticosteroid use: Need for further evidence?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 5:3, pages 136-149.
Read now
Read now
Jennifer Cook, Chloe Bloom, Jen Lewis, Zoe Marjenberg, Jaime Hernando Platz & Sue Langham. (2021) Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. Journal of Market Access & Health Policy 9:1.
Read now
Read now
Antoni Sicras-Mainar, Francisco J de Abajo & José Luis Izquierdo-Alonso. (2020) Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3291-3302.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D’Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Don D. Sin & Darcy D. Marciniuk. (2019) Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 3:4, pages 210-232.
Read now
Read now
Sergey Avdeev, Zaurbek Aisanov, Vladimir Arkhipov, Andrey Belevskiy, Igor Leshchenko, Svetlana Ovcharenko, Evgeny Shmelev & Marc Miravitlles. (2019) Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1267-1280.
Read now
Read now
Articles from other publishers (21)
Richard Beasley, Pepa Bruce & Lee Hatter. (2023) ICS/formoterol maintenance and reliever therapy: how far beyond asthma?. Thorax 78:5, pages 430-431.
Crossref
Crossref
Susan Muiser, Kai Imkamp, Dianne Seigers, Nynke J Halbersma, Judith M Vonk, Bart H D Luijk, Gert-Jan Braunstahl, Jan-Willem van den Berg, Bart-Jan Kroesen, Janwillem W H Kocks, Irene H Heijink, Helen K Reddel, Huib A M Kerstjens & Maarten van den Berge. (2023) Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax 78:5, pages 451-458.
Crossref
Crossref
S. N. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, A. A. Vizel, I. V. Demko, A. V. Emelyanov, A. A. Zaycev, G. L. Ignatova, N. P. Kniajeskaia, L. M. Kudelya, I. V. Leshchenko, S. I. Ovcharenko, A. I. Sinopalnikov, I. N. Trofimenko, V. D. Fedotov & R. F. Khamitov. (2023) Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice. PULMONOLOGIYA 33:1, pages 109-118.
Crossref
Crossref
Jieon Lee, Kairui Feng, Denise S. Conti, Ross Walenga, Michael Wientjes, Hezhen Wang, Bryan Newman, Liangfeng Han, Sneha Dhapare, Elizabeth Bielski, Andrew Babiskin, Fang Wu, Mark Donnelly, Myong‐Jin Kim, Wenlei Jiang, Markham C. Luke, Lanyan Fang & Liang Zhao. (2022) Considerations for the Forced Expiratory Volume in 1 Second‐Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug Products. Clinical Pharmacology & Therapeutics 112:5, pages 982-989.
Crossref
Crossref
Hyun Woo Lee, Hee Moon Park, Eun Jin Jang & Chang-Hoon Lee. (2022) Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Scientific Reports 12:1.
Crossref
Crossref
Paola Rogliani, Josuel Ora, Francesco Cavalli, Mario Cazzola & Luigino Calzetta. (2022) Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score. Journal of Clinical Medicine 11:15, pages 4491.
Crossref
Crossref
A. G. Chuchalin, S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, I. V. Leshchenko, S. I. OvcharenkoE. I. Shmelev. (2022) Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. PULMONOLOGIYA 32:3, pages 356-392.
Crossref
Crossref
Domenico Maurizio Toraldo, Emanuele Rizzo & Luana Conte. (2022) Effects of inhaled corticosteroids (ICS) on lung microbiota and local immune response in long-term treatment of chronic obstructive pulmonary disease (COPD): utility of titration and therapeutic index. Naunyn-Schmiedeberg's Archives of Pharmacology 395:7, pages 849-858.
Crossref
Crossref
Mohamed S. Al-Moamary, Nurdan Köktūrk, Majdy M. Idrees, Elif Şen, George Juvelekian, Wajdy Abi Saleh, Zaid Zoumot, Naser Behbehani, Ashraf Hatem, Hosam H. Masoud, Abdelmadjid Snouber & Richard N. van Zyl-Smit. (2021) Unmet need in the management of chronic obstructive pulmonary disease in the Middle East and Africa region: An expert panel consensus. Respiratory Medicine 189, pages 106641.
Crossref
Crossref
V. V. Salukhov, E. V. Kryukov, M. A. Kharitonov, V. P. Sereda & A. A. Minakov. (2021) Triple therapy in a single inhaler for chronic obstructive pulmonary disease: clinical studies and case report (real practice). Meditsinskiy sovet = Medical Council:16, pages 174-184.
Crossref
Crossref
Henock G Yebyo, Julia Braun, Dominik Menges, Gerben ter Riet, Mohsen Sadatsafavi & Milo A Puhan. (2021) Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit–harm modelling study. The Lancet Digital Health 3:10, pages e644-e653.
Crossref
Crossref
Sarah de Oliveira Rodrigues, Carolina Medina Coeli da Cunha, Giovanna Martins Valladão Soares, Pedro Leme Silva, Adriana Ribeiro Silva & Cassiano Felippe Gonçalves-de-Albuquerque. (2021) Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease. Pharmaceuticals 14:10, pages 979.
Crossref
Crossref
Sundeep Salvi, Akash Balki, Srikanth Krishnamurthy, Sagar Panchal, Saiprasad Patil, Rahul Kodgule, Hitesh Khandagale, Amol Pendse, Wen Wu, Shabbir Rangwala, Monika Tandon & Hanmant Barkate. (2021) Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. ERJ Open Research 7:3, pages 00255-2021.
Crossref
Crossref
Benjamin David, Mona Bafadhel, Leo Koenderman & Antony De Soyza. (2021) Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax 76:2, pages 188-195.
Crossref
Crossref
I. N. Trofimenko & B. A. Chernyak. (2020) Extrafine combination beclomethasone dipropionate/ formoterol therapy in obstructive lung diseases. Meditsinskiy sovet = Medical Council:11, pages 108-115.
Crossref
Crossref
S. N. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, I. V. Leshchenko, S. I. Ovcharenko, A. V. Emel'yanov, I. V. Demko, G. L. Ignatova, I. N. Trofimenko & E. I. Shmelev. (2020) Inhalation glucocorticosteroids in the treatment of chronic obstructive pulmonary disease. Russian Pulmonology 30:3, pages 330-343.
Crossref
Crossref
Cristina Fernández-Paz, Sara Rojas, Pablo Salcedo-Abraira, Teresa Simón-Yarza, Carmen Remuñán-López & Patricia Horcajada. (2020) Metal–Organic Framework Microsphere Formulation for Pulmonary Administration. ACS Applied Materials & Interfaces 12:23, pages 25676-25682.
Crossref
Crossref
Ariadna Fernández-Calvet, Begoña Euba, Lucía Caballero, Roberto Díez-Martínez, Margarita Menéndez, Carlos Ortiz de Solórzano, José Leiva, Vicente Micol, Enrique Barrajón-Catalán & Junkal Garmendia. (2019) Preclinical Evaluation of the Antimicrobial-Immunomodulatory Dual Action of Xenohormetic Molecules against Haemophilus influenzae Respiratory Infection. Biomolecules 9:12, pages 891.
Crossref
Crossref
Andreas Rembert Koczulla, Timm Greulich & Marco Idzko. (2019) Therapie der COPD: Welcher Patient von welcher Medikation profitiert. Deutsches Ärzteblatt Online.
Crossref
Crossref
S. N. Avdeev, Z. R. Aisanov, V. V. Arkhipov, A. S. Belevskiy, I. V. Leshchenko, S. I. Ovcharenko, E. I. Shmelev & M. Miravitls. (2019) Withdrawal of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Russian Pulmonology 29:3, pages 334-345.
Crossref
Crossref
Lixin Peng, Bin Du, Liangliang Sun, Yuguang Zhao & Xinping Zhang. (2019) Short‑term efficacy and safety of prednisone in herpes zoster and the effects on IL‑6 and IL‑10. Experimental and Therapeutic Medicine.
Crossref
Crossref